argenx SE

$289.38
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$2.56 (+0.89%) Today

$0.00 (0.00%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell argenx SE and other stocks, options, and ETFs commission-free!

About ARGX

argenx SE American Depositary Shares, also called argenx SE, is a clinical-stage biotechnology company, which engages in the development of antibody-based therapies for the treatment of autoimmune diseases and cancer. Its products include ARGX-113 for the treatment of autoimmune disease myasthenia gravis and ARGX-110 for the treatment of hematological cancer acute myeloid leukemia. The company was founded by Hans J. W. de Haard, Torsten Dreier, and Tim van Hauwermeiren on April 25, 2008 and is headquartered in Breda, the Netherlands. The listed name for ARGX is argenx SE American Depositary Shares.

CEO

Tim van Hauwermeiren

Employees

188

Headquarters

Breda, Noord-Brabant

Founded

2008

Market Cap

13.60B

Price-Earnings Ratio

—

Dividend Yield

—

Average Volume

153.52K

High Today

$291.23

Low Today

$285.71

Open Price

$286.33

Volume

124.20K

52 Week High

$291.23

52 Week Low

$103.75

Collections

Analyst Ratings

75%

of 20 ratings

Buy

75%

Hold

25%

Sell

ARGX Earnings

-$3.96

-$2.58

-$1.19

$0.19

Q1 FY19

Q2 FY19

Q3 FY19

Q4 FY19

Q1 FY20

Q2 FY20

Q3 FY20

Q4 FY20

Estimated

— per share

Actual

Expected Feb 25, Pre-Market